Therapeutics and Clinical Risk Management (Jan 2023)
Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
Abstract
Christina Shaw,1 William Gibson2 1Division of Geriatric Medicine, University of British Columbia, Vancouver, British Columbia, Canada; 2Division of Geriatric Medicine, University of Alberta, Edmonton, Alberta, CanadaCorrespondence: William Gibson, Division of Geriatric Medicine, University of Alberta, 1-198 Clinical Sciences Building, 11350 83 Ave NW, Edmonton, Alberta, T6E 2K4, Canada, Tel +1 780 248 1969, Fax +1 780 492 2874, Email [email protected]: Lower urinary tract symptoms (LUTS), including urgency, frequency, and urgency incontinence, are highly prevalent in the general population and increase in prevalence with increasing age. All LUTS, but notable urgency and urgency incontinence, are associated with negative impact on quality-of-life (QoL), with multiple aspects of QoL affected. Urgency and urgency incontinence are most commonly caused by overactive bladder (OAB), the clinical syndrome of urinary urgency, usually accompanied by increased daytime frequency and/or nocturia in the absence of infection or other obvious etiology, which may be treated with conservative and lifestyle interventions, bladder antimuscarinic drugs, and, more recently, by mirabegron, a β 3 agonist. This narrative review describes the impact of OAB on QoL, quantifies this impact, and outlines the evidence for the use of mirabegron in the treatment of, and improvement in QoL in, people with OAB.Keywords: lower urinary tract symptoms, incontinence, quality-of-life, health-related quality-of-life, mirabegron
